No Data
No Data
TD Cowen Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $65
TD Cowen analyst Tara Bancroft initiates coverage on $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and sets the target price at $65.According to TipRanks data, the analyst has a success
Express News | Protagonist Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Target Price $65
The 8.6% Return This Week Takes Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Five-year Gains to 231%
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $50
H.C. Wainwright analyst Douglas Tsao maintains $Protagonist Therapeutics(PTGX.US)$ with a buy rating, and adjusts the target price from $40 to $50.According to TipRanks data, the analyst has a
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Belite Bio, Inc. ADR (BLTE) and Protagonist Therapeutics (PTGX)
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines